Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Medmira (MIR) Stock Price & Analysis

40 Followers

MIR Stock Chart & Stats

CA$0.06CA$0.00(10.00%)
At close: 4:00 PM EST
C$0.05C$0.06C$0.07Aug 10Aug 24Sep 8Sep 21Oct 8Oct 19Nov 2
Day’s Range
CAD 0.06 - CAD 0.06
52-Week Range
CAD 0.05 - CAD 0.08
Previous Close
CAD 0.05
Volume
N/A
Average Volume (3M)
35.96K
Market Cap
CAD 35.09M
Enterprise Value
CAD 55.31T
Total Cash (Recent Filing)
CAD 0
Total Debt (Recent Filing)
CAD 17.42M
Price to Earnings (P/E)
―
Beta
0.85
Next Earnings
Dec 02, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Rebound

The TTM revenue rebound indicates materially stronger product demand and market activity. If sustained, higher sales can improve operating leverage and support scale across healthcare and public-health customers, although profitability conversion remains unproven.

Reusable RVF Technology Platform

An RVF platform supporting HIV and HCV assays gives MedMira a reusable technology base rather than a single-product proposition. Broader infectious-disease applications can support product extensions, channel reach and future customer retention.

Recurring Consumables Model

Diagnostic kits are bought by clinics, hospitals, laboratories, public-health agencies and distributors. Continued testing creates a structural opportunity for repeat orders, while direct and distribution channels can widen access without relying on one customer route.

Bears Say

Persistent Unprofitability

Deeply negative gross margin and continuing operating and net losses show that revenue growth has not yet translated into viable unit economics. Without sustained gross-profit improvement, future scale could increase losses rather than create durable earnings.

Negative Cash Generation

Negative operating cash flow and free cash flow in every period indicate the business cannot currently fund itself. Ongoing burn raises dependence on external financing and constrains investment in product development, manufacturing and commercialization.

Stressed Balance Sheet

Negative shareholders’ equity, substantial debt and limited assets leave little balance-sheet cushion. This leverage profile increases solvency risk and may weaken negotiating power with lenders, suppliers and strategic partners.

Medmira News

MIR FAQ

What was Medmira’s price range in the past 12 months?
Medmira lowest stock price was C$0.05 and its highest was C$0.08 in the past 12 months.
What is Medmira’s market cap?
Medmira’s market cap is C$35.09M.
When is Medmira’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medmira’s earnings last quarter?
Medmira released its earnings results on Jun 30, 2026. The company reported -C$0.001 earnings per share for the quarter.
Is Medmira overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Medmira pay dividends?
Medmira does not currently pay dividends.
What is Medmira’s EPS estimate?
Medmira’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medmira have?
Medmira has 701,730,600 shares outstanding.
What happened to Medmira’s price movement after its last earnings report?
Medmira reported an EPS of -C$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medmira?
Currently, no hedge funds are holding shares in TSE:MIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology